<DOC>
	<DOCNO>NCT00135577</DOCNO>
	<brief_summary>Study SB-767905/008 multicenter study evaluate effectiveness safety multiple dosage regimens investigational drug treatment constipation due prescription pain medication participant cancer pain . Study ABD101684 serve extension Study SB-767905/008 offer continue access blind investigational product participant complete original study . The purpose Study ABD101684 evaluate safety efficacy alvimopan compare placebo subject complete Study SB-767905/008 elect participate extension study .</brief_summary>
	<brief_title>Study 767905/008 Extension Study : Alvimopan Treatment Opioid-Induced Bowel Dysfunction Cancer Pain Subjects</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Alvimopan</mesh_term>
	<criteria>Completed GSK sponsor alvimopan ( opioidinduced bowel dysfunction ) OBD study subject cancerrelated pain , e.g . SB767905/008 . Taking full agonist opioid therapy cancer relate pain . Met entry criterion OBD original study per investigator continue require therapy management OBD . Capable complete paper questionnaire study visit . Unable eat drink . Taking opioids management drug addiction . Unable use rescue laxative provide . Inappropriately manage severe constipation put subject risk complication . Has gastrointestinal ( GI ) pelvic disorder know affect bowel transit . Concomitant medication ( ) , medical condition , clinically significant laboratory abnormality could jeopardize subject also contraindicate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>opioids</keyword>
	<keyword>constipation</keyword>
	<keyword>opioid-induced bowel dysfunction</keyword>
</DOC>